



ATOPIC ECZEMA/DERMATITIS

UPDATE ON IMMUNOPATHOGENESIS AND BIOLOGIC TREATMENT OF ATOPIC DERMATITIS

Salah Al Rubaie⁽¹⁾

Dr. Salah Al Rubaie Clinic, Dermatology, Dubai, United Arab Emirates⁽¹⁾

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases that affect both children and adults. The prevalence of Atopic dermatitis has shown a worldwide increase in the past 30 years, and affect around 15-30% of children and 2-10% of adults. Even though most of patients respond satisfactory to topical anti-inflammatory drugs, about 10-15% require one or more systemic treatments to achieve good control of their disease. The updated knowledge in the immunopathogenesis of AD has allowed research on new therapeutic targets with very promising results in the field of biological therapy. I think we are seeing a few new biologics in development and new biologic treatment is recently launch in the market that may change the way that people approach the treatment of severe atopic dermatitis. In my talk, I will review the update of Immunopathogenesis in relation to the mechanism of Biologics in treatment of Atopic Dermatitis.

